S
Sharon Mavroukakis
Researcher at Stanford University
Publications - 56
Citations - 15328
Sharon Mavroukakis is an academic researcher from Stanford University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 24, co-authored 38 publications receiving 14029 citations. Previous affiliations of Sharon Mavroukakis include National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines.
Steven A. Rosenberg,Richard M. Sherry,Kathleen E. Morton,James Chih-Hsin Yang,Suzanne L. Topalian,Richard E. Royal,Udai S. Kammula,Nicholas P. Restifo,Michael S. Hughes,Susan L. Schwarz,Lien T. Ngo,Sharon Mavroukakis,Donald E. White +12 more
TL;DR: It is indicated that mixing peptides in the same emulsion can alter reactivity compared with peptides injected separately by mechanisms that may include the induction of localized nonspecific inflammation or competitive binding of peptides to major histocompatibility complex molecules.
Journal ArticleDOI
Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas.
Massimo Fantini,Justin M. David,Olga Saric,Alexander Dubeykovskiy,Yongzhi Cui,Sharon Mavroukakis,Andrew Bristol,Christina M. Annunziata,Kwong Y. Tsang,Philip M. Arlen +9 more
TL;DR: Findings indicate that NEO-201 warrants clinical testing as both a novel diagnostic and therapeutic agent for the treatment of a broad variety of carcinomas.
Journal ArticleDOI
A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer.
Muhammad Shaalan Beg,Nilofer S. Azad,Sandip Pravin Patel,Jose R. Torrealba,Sharon Mavroukakis,Melony A. Beatson,XuePing Wang,Philip M. Arlen,Michael A. Morse +8 more
TL;DR: Treatment with the NEO-102, in this first-in-human study, is well tolerated with a manageable safety profile, and a maximum tolerated dose of 3 mg/kg has been established.
Journal ArticleDOI
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
Heather E. Stefanski,Anne Eaton,Christina Baggott,Jenna Rossoff,Michael R. Verneris,Amy E. Keating,Snehit Prabhu,Holly L. Pacenta,Christine L Phillips,Julie-An Talano,Amy Moskop,Steven P. Margossian,G.D. Myers,Nicole Karras,Patrick A. Brown,Muna Qayed,Michelle L. Hermiston,Prakash Satwani,Christa Krupski,Rachel Wilcox,Cara A. Rabik,Vanessa A Fabrizio,Vasant Chinnabhandar,A. Yasemin Goksenin,Emily Egeler,Sharon Mavroukakis,Kevin J. Curran,Crystal L. Mackall,Theodore W. Laetsch,Liora M. Schultz +29 more
TL;DR:
Journal ArticleDOI
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia
Liora M. Schultz,Anne Eaton,Christina Baggott,Jenna Rossoff,Snehit Prabhu,Amy E. Keating,Christa Krupski,Holly L. Pacenta,Christine Philips,Julie-An Talano,Amy Moskop,Susanne H.C. Baumeister,G.D. Myers,Nicole Karras,Patrick O. Brown,Muna Qayed,Michelle L. Hermiston,Prakash Satwani,Rachel Wilcox,Cara A. Rabik,Vanessa A Fabrizio,Vasant Chinnabhandar,Michael Kunicki,Sharon Mavroukakis,Emily Egeler,Yi-min Li,Crystal L. Mackall,Kevin J. Curran,Michael R. Verneris,Theodore W. Laetsch,Heather E. Stefanski +30 more
TL;DR: In this article , the authors conducted a retrospective multi-institutional study of 80 children and young adults with B-cell acute lymphoblastic leukemia experiencing nonresponse (n = 23) or relapse after tisagenlecleucel.